1.
Clin Hematol Int
; 6(2): 46-50, 2024.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38817306
RESUMO
We present the case of a dialyzed patient with relapsed IgA and lambda free light chain multiple myeloma treated with elranatamab. Despite end-stage renal impairment, the treatment with anti-B cell maturation antigen (BCMA)xCD3 bispecific antibody proved to be feasible, without unexpected side effects. Increased attention to infectious risk is crucial for these doubly fragile patients.